Comparison of Bleeding in Patients With Nonvalvular Atrial Fibrillation Treated With Ximelagatran or Warfarin
Authors:
- James D. DouketisJDJames D. Douketis
- Karin ArneklevKAKarin Arneklev
- Samuel Z. GoldhaberSGSamuel Z. Goldhaber
- John SpandorferJSJohn Spandorfer
- Frank HalperinFHFrank Halperin
- Jay HorrowJHJay Horrow
Open Access
- 24 April 2006
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 166 (8) , 853-859
Abstract
In patients with nonvalvular atrial fibrillation, conventional therapy uses warfarin sodium to prevent intracardiac thrombosis and stroke.1 Ximelagatran is the first of a new class of oral anticoagulants, direct thrombin inhibitors, that bind to circulating and clot-bound thrombin.2 The Stroke Prevention Using Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF) III and V trials found that fixed-dose ximelagatran, 36 mg twice daily, prevents stroke as well as dose-adjusted warfarin (target international normalized ratio [INR], 2.0-3.0) in patients with nonvalvular atrial fibrillation.3-5Keywords
This publication has 20 references indexed in Scilit:
- Systematic Overview of Warfarin and Its Drug and Food InteractionsArchives of internal medicine (1960), 2005
- The Effect of Excessive Anticoagulation on Mortality and Morbidity in Hospitalized Patients With Anticoagulant-Related Major HemorrhageArchives of internal medicine (1960), 2004
- Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trialThe Lancet, 2003
- Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)American Heart Journal, 2003
- Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearanceClinical Pharmacology & Therapeutics, 2002
- Management and dosing of warfarin therapyThe American Journal of Medicine, 2000
- Acetaminophen and Other Risk Factors for Excessive Warfarin AnticoagulationJAMA, 1998
- Anticoagulant-related bleeding: Clinical epidemiology, prediction, and preventionThe American Journal of Medicine, 1993
- Risk Factors for Complications of Chronic Anticoagulation: A Multicenter StudyAnnals of Internal Medicine, 1993
- Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.Journal of Clinical Investigation, 1990